| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
In end stage renal disease(ESRD) patients, we found that mean plasma S100A12 level was 2.3-fold higher than that in control subjects and that this level was an independent factorassociated with the prevalence of atherosclerotic cardiovascular diseases(CVD) such as ischemic heart disease including myocardial infarction and angina pectoris, symptomatic stroke and symptomatic peripheral vascular disease. Therefore, we anticipate an important role for S100A12 as a novel biomarker to predict CVD in patients with ESRD. Prospective and interventional studies are currently ongoing to further elucidate the relationship between plasma S100A12 level and CVD.
|
